Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Therma Bright (TSXV:THRM) to distribute 15 minute COVID-19 antibody test

 Trevor Abes Trevor Abes , The Market Online
0 Comments| May 6, 2021

{{labelSign}}  Favorites
{{errorMessage}}

  • Therma Bright (THRM) has entered into an agreement to white label and distribute a 15 minute COVID-19 antibody test
  • The new product will be branded Therma Bright's AcuVid COVID-19 Rapid Antibody Test
  • It will detect IgG and IgM antibodies against SARS-CoV-2 in those currently infected or who have been previously infected
  • The test uses a small amount of blood and has 96.6 per cent sensitivity
  • Therma Bright is focused on providing consumers and medical professionals with quality medical devices that address their unmet needs
  • Therma Bright (THRM) is up by 3.52 per cent and is currently trading at $0.44 per share

Therma Bright (THRM) has entered into an agreement to white label and distribute a 15 minute COVID-19 antibody test.

The new product will be branded Therma Bright's AcuVid COVID-19 Rapid Antibody Test and will detect IgG and IgM antibodies against SARS-CoV-2.

The test uses a small amount of blood and has a 96.6 per cent sensitivity to individuals currently infected or who have previously been infected but went undiagnosed.

The test will also aid in determining antibodies generated by those who have received a COVID-19 vaccine.

The antibody test received a CE mark in Europe and ANVISA regulatory clearance in Brazil.

Rob Fia, CEO of Therma Bright, commented,

"The world is realizing the benefits and challenges with these COVID-19 vaccines, and this antibody test solution will aid in helping our global citizens understand if they have the SARS-CoV-2 antibodies to help them better fight the virus. We're currently in discussions to supply our new AcuVid COVID-19 Rapid Antibody Test to selected customers in Europe and South America."

Therma Bright is not making any express or implied claims that its test product has the ability to eliminate or cure COVID-19 or the SARS-CoV-2 virus.

Therma Bright is focused on providing consumers and medical professionals with quality medical devices that address their unmet needs.

Therma Bright (THRM) is up by 3.52 per cent and is currently trading at $0.44 per share as of 9:30 am ET.



{{labelSign}}  Favorites
{{errorMessage}}


Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today

Featured Company